Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2005-4-25
pubmed:abstractText
Alzheimer's disease (AD) is characterized by the presence of aggregates of the amyloid-beta (A beta) peptide in the brain. These aggregates manifest themselves as senile plaques and cerebrovascular amyloid angiopathy (CAA). While traditional histochemical approaches can easily identify these deposits in postmortem tissue, only recently have specific ligands been developed to target A beta in living patients using positron emission tomography (PET). Successful detection of A beta pathology in patients will enable definitive preclinical diagnosis of AD, and enable quantitative evaluation of the efficacy of anti-A beta therapeutics developed to treat the disease. PET scanning, however, has several disadvantages including high cost, low availability, and the requirement for radioactive tracers. We describe recent progress in the development of techniques for imaging A beta deposits noninvasively using optical approaches. Successful development of an optical detection platform would enable inexpensive, accessible, nonradioactive detection of the A beta deposits found in AD.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1083-3668
pubmed:author
pubmed:copyrightInfo
Copyright 2005 Society of Photo-Optical Instrumentation Engineers
pubmed:issnType
Print
pubmed:volume
10
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
11007
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed:articleTitle
Development of an optical approach for noninvasive imaging of Alzheimer's disease pathology.
pubmed:affiliation
Massachusetts General Hospital, MassGeneral Institute for Neurodegenerative Disease, Department of Neurology/Alzheimer's Disease Research Unit, 114 16th Street, Charlestown, Massachusetts 02129, USA.
pubmed:publicationType
Journal Article, Evaluation Studies